Standardized salvia miltiorrhiza extract suppresses hepatic stellate cell activation and attenuates steatohepatitis induced by a methionine-choline deficient diet in mice

Molecules

Volumn 19, Issue 6, 2014, Pages 8189-8211

  Lee, Hak Sung ^a,b   Son, Woo Chan ^c   Ryu, Jae Eun ^c   Koo, Bon Am ^b   Kim, Yeong Shik ^a  

^a Seoul National University   (South Korea)

^b Samil Pharmaceutical Co Ltd   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatic stellate cell (HSC); Methionine choline deficient (MCD); MMP 2; MMP 9; Non alcoholic steatohepatitis (NASH); Salvia miltiorrhiza; Tanshinone IIA; TGF 1; TNF

Indexed keywords

CHOLINE; HYDROGEN PEROXIDE; METHIONINE; PLANT EXTRACT;

ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CHEMISTRY; DEFICIENCY; DIET; DRUG EFFECTS; FATTY LIVER; HUMAN; MALE; MOUSE; SALVIA MILTIORRHIZA; STELLATE CELL;

ANIMALS; CHOLINE; DIET; FATTY LIVER; HEPATIC STELLATE CELLS; HUMANS; HYDROGEN PEROXIDE; MALE; METHIONINE; MICE; MICE, INBRED C57BL; PLANT EXTRACTS; SALVIA MILTIORRHIZA;

EID: 84903289242     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19068189     Document Type: Article

References (39)

1. De Alwis N.M.; Day C.P. Non-alcoholic fatty liver disease: The mist gradually clears. J. Hepatol. 2008 48 S104-S112.
2. Marchesini G.; Brizi M.; Morselli-Labate A.M .; Bianchi G.; Bugianesi E.; McCullough A.J.; Forlani G.; Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999 107 450-455.
3. Brownin g J.D.; Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004 114 147-152.
4. Schwimmer J.B.; Behling C.; Newbury R.; Deutsch R.; Nievergelt C.; Schork N.J.; Lavine J.E. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005 42 641-649.
5. Jansen P.L. Non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2004 16 1079-1085.
6. Wanless I.R.; Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: A four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 2004 24 99-106.
7. Harrison S.A.; Kadakia S.; Lang K.A.; Schenker S. Nonalcoholic steatohepatitis: What we know in the new millennium. Am. J. Gastroenterol. 2002 97 2714-2724.
8. Cortez-Pinto H.; de Moura M.C.; Day C.P. Non-alcoholic steatohepatitis: From cell biology to clinical practice. J. Hepatol. 2006 44 197-208.
9. Anstee Q.M.; Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006 87 1-16.
10. Leclercq I.A.; Farrell G.C.; Field J.; Bell D.R.; Gonzalez F.J.; Robertson G.R. Cyp2e1 and cyp4a as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 2000 105 1067-1075.
11. Oliveira C.P.; da Costa Gayotto L.C.; Tatai C.; Della Bina B.I.; Janiszewski M.; Lima E.S.; Abdalla D.S.; Lopasso F.P.; Laurindo F.R.; Laudanna A.A. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease in rats fed with a choline-deficient diet. J. Cell Mol. Med. 2002 6 399-406.
12. Tilg H.; Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000 343 1467-1476.
13. Polyzos S.A.; Kountouras J.; Zavos C. Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med. 2009 9 299-314.
14. Tilg H.; Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010 52 1836-1846.
15. Ikejima K.; Takei Y.; Honda H.; Hirose M.; Yoshikawa M.; Zhang Y.J.; Lang T.; Fukuda T.; Yamashina S.; Kitamura T.; et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002 122 1399-1410.
16. Bissell D.M.; Roulot D.; George J. Transforming growth factor beta and the liver. Hepatology 2001 34 859-867.
17. Knittel T.; Muller L.; Saile B.; Ramadori G. Effect of tumour necrosis factor-alpha on proliferation activation and protein synthesis of rat hepatic stellate cells. J. Hep atol. 1997 27 1067-1080.
18. Han Y.P.; Tuan T.L.; Hughes M.; Wu H.; Garner W.L. Transforming growth factor-beta-and tumor necrosis factor-alpha-mediated induction and proteolytic activation of mmp-9 in human skin. J. Biol. Chem. 2001 276 22341-22350.
19. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000 279 G245-G249.
20. Murphy G. Docherty A.J The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell Mol. Biol. 1992 7 120-125.
21. Arthur M.J.; Friedma n S.L.; Roll F.J.; Bissell D.M. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type iv) collagen. J. Clin. Invest. 1989 84 1076-1085.
22. Knittel T.; Mehde M.; Kobold D.; Saile B.; Dinter C.; Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: Regulation by tnf-alpha and tgf-beta1. J. Hepatol. 1999 30 48-60.
23. Han J.Y.; Fan J.Y.; Horie Y.; Miura S.; Cui D.H.; Ishii H.; Hibi T.; Tsuneki H.; Kimura I. Ameliorating effects of compounds derived fr om salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol. Ther. 2008 117 280-295.
24. Jang S.I.; Kim H.J.; Kim Y.J.; Jeong S. I.; You Y.O. Tanshinone iia inhibits lps-induced nf-kappab activation in raw 264.7 cells: Possible involvement of the nik-ikk erk1/2 p38 and jnk pathways. Eur. J. Pharmacol. 2006 542 1-7.
25. Ng T.B.; Liu F.; Wang Z.T. Antioxidative activity of natural products from plants. Life Sci. 2000 66 709-723.
26. Sung H.J.; Choi S.M.; Yoon Y.; An K.S. Tanshinone iia an ingredient of salvia miltiorrhiza bunge induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp. Mol. Med. 1999 31 174-178.
27. Fan G.W.; Gao X.M.; Wang H.; Zhu Y.; Zhang J.; Hu L.M.; Su Y.F.; Kang L.Y.; Zhang B.L. The anti-inflammatory activities of tanshinone iia an active component of tcm are mediated by estrogen receptor activation and inhibition of inos. J. Stero id Biochem. Mol. Biol. 2009 113 275-280.
28. Yin H.Q.; Kim Y.S.; Choi Y.J.; Kim Y.C.; Sohn D.H.; Ryu S.Y.; Lee B.H. Effects of tanshinone iia on the hepatotoxicity and gene express ion involved in alcoholic liver disease. Arch. Pharm. Res. 2008 31 659-665.
29. Song H.Y.; Zhang L.; Pan J.L.; Yang L.L.; Ji G. Bioactivity of five components of Chinese herbal formula jian gzhi granules against hepatocellular steatosis. J. Integr. Med. 2013 11 262-268.
30. Fang Z.Y.; Lin R.; Yuan B.X.; Liu Y.; Zhang H. Tanshinone iia inhibits atherosclerotic plaque formation by down-regulating mmp-2 and mmp-9 expression in rabbits fed a high-fat diet. Life Sci. 2007 81 1339-1345.
31. Vizzutti F.; Provenzano A.; Galastri S.; Milani S.; Delogu W.; Novo E.; Caligiuri A.; Zamara E.; Arena U.; Laffi G.; et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab. Invest. 2010 90 104-115.
32. Kulinski A.; Vance D.E.; Vance J.E. A choline-deficient diet in mice inhibits neither the cdp-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein b secretion. J. Biol. Chem. 2004 279 23916-23924.
33. Zhang S.; Wang J.; Liu Q.; Harnish D.C. Farnesoid x receptor agonist way-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009 51 380-388.
34. Gao D.; Wei C.; Chen L.; Huang J.; Yang S.; Diehl A.M. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am. J. Physiol. Gastrointest . Liver Physiol. 2004 287 G1070-G1077.
35. Gebhardt R. Oxidative stress plant-derived antioxidants and liver fibrosis. Planta Med. 2002 68 289-296.
36. Pociask D .A.; Sime P.J.; Brody A.R. Asbestos-derived reactive oxygen species activate tgf-beta1. Lab. Invest. 2004 84 1013-1023.
37. Albright C.D.; Salganik R.I.; Craciunescu C.N.; Mar M.H.; Zeisel S.H. Mitochondrial and microsomal derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in immortalized rat hepatocytes. J. Cell Biochem. 2003 89 254-261.
38. Kayanoki Y.; Fujii J.; Suzuki K.; Kawata S.; Matsuzawa Y.; Taniguchi N. Suppression of antioxidative enzyme expression by transforming growth factor-beta 1 in rat hepatocytes. J. Biol. Chem. 1994 269 15 488-15492.
39. Brunt E.M.; Kleiner D.E.; Wilson L.A.; Belt P.; Neuschwander-Tetri B.A.; Network N.C.R. Nonalcoholic fatty liver disease (nafld) activity score and the histopathologic diagnosis in nafld: Distinct clinicopathologic meanings. Hepatology 2011 53 810-820.